On Wednesday, May 30 executives and guests of Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company and world's largest generic drug maker, will visit the New York Stock Exchange (NYSE) to celebrate the company's transfer of its stock listing to the NYSE from NASDAQ. Teva Pharmaceutical trades on the NYSE under its current stock symbol, "TEVA" beginning on May 30. In honor of the occasion, Chairman of the Board of Directors, Dr. Phillip Frost and President and CEO Dr. Jeremy M. Levin, joined by members of Teva Pharmaceutical's leadership team, ring The Opening BellSM.|
Watch a live webcast of The Opening Bell at 9:29 a.m. ET on May 30, 2012. The archive will be available shortly after the event.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011. (Source: Teva Pharmaceutical Industries Ltd.)